LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

19.99 -0.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.58

Максимум

20.22

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+106.15% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-149M 1.7B
Предишно отваряне	20.39
Предишно затваряне	19.99

Настроения в новините

By Acuity

50%

159 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20.05.2026 г., 22:52 ч. UTC

Значими двигатели на пазара

Osisko Shares Fall on Planned Convertible Notes Offering

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20.05.2026 г., 23:44 ч. UTC

Печалби

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20.05.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20.05.2026 г., 23:15 ч. UTC

Пазарно говорене

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20.05.2026 г., 23:14 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20.05.2026 г., 23:02 ч. UTC

Пазарно говорене

KMD Brands Faces Two Testing Hurdles -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 22:27 ч. UTC

Пазарно говорене

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20.05.2026 г., 22:14 ч. UTC

Пазарно говорене

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20.05.2026 г., 22:10 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20.05.2026 г., 22:00 ч. UTC

Печалби

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20.05.2026 г., 21:38 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20.05.2026 г., 21:27 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20.05.2026 г., 21:20 ч. UTC

Печалби

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20.05.2026 г., 21:19 ч. UTC

Печалби

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20.05.2026 г., 21:18 ч. UTC

Печалби

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20.05.2026 г., 21:16 ч. UTC

Печалби

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

106.15% нагоре

12-месечна прогноза

Среден 39.91 USD 106.15%

Висок 57 USD

Нисък 29 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

159 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.